|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Aplastic anemia and severe pancytopenia during treatment with peg-interferon,ribavirin and telaprevir for chronic hepatitis C显示文摘Telaprevir and Boceprevir are the first direct acting antivirals approved for chronic hepatitis C in combination with peg-interferon alfa and ribavirin.Pancytopenia due to myelotoxicity caused by these drugs may occur,but severe hematological abnormalities or aplastic anemia(AA) have not been described.We collected all cases of severe pancytopenia observed during triple therapy with telaprevir in four Spanish centers since approval of the drug in 2011.Among 142 cirrhotic patients receiving treatment,7 cases of severe pancytopenia(5%) were identified and three were consistent with the diagnosis of AA.Mean age was 59 years,five patients had compensated cirrhosis and two patients had severe hepatitis C recurrence after liver transplantation.Severe pancytopenia was diagnosed a median of 10 wk after the initiation of therapy.Three patients had pre-treatment hematological abnormalities related to splenomegaly.In six patients,antiviral treatment was interrupted at the onset of hematological abnormalities.Two patients died due to septic complications and one patient due to acute alveolar hemorrhage.The remaining patients recovered.Severe pancytopenia and especially AA,are not rare during triple therapy with telaprevir in patients with advanced liver disease.Close monitoring is imperative in this setting to promptly detect serious hematological disorders and to prevent further complications. | Sabela Lens Jose L Calleja Ana Campillo Jose A Carrion Teresa Broquetas Christie Perello Juan de la Revilla Zoe Marino Maria-Carlota Londono Jose M Sanchez-Tapias Alvaro Urbano-Ispizua Xavier Forns | 2015 | World Journal of Gastroenterology2015，21，17： | 4 |
| 2 | Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients显示文摘BACKGROUND Hepatitis B e antigen-negative chronic hepatitis B patients under nucleos(t)ids analogues(NAs)rarely achieve hepatitis B surface antigen(HBsAg)loss.AIM To evaluate if the addition of pegylated interferon(Peg-IFN)could decrease HBsAg and hepatitis B core-related antigen(HBcrAg)levels and increase HBsAg loss rate in patients under NAs therapy.METHODS Prospective,non-randomized,open-label trial evaluating the combination of Peg-IFN 180μg/week plus NAs during forty-eight weeks vs NAs in monotherapy.Hepatitis B e antigen-negative non-cirrhotic chronic hepatitis B patients of a tertiary hospital,under NAs therapy for at least 2 years and with undetectable viral load,were eligible.Patients with hepatitis C virus,hepatitis D virus or human immunodeficiency virus co-infection and liver transplanted patients were excluded.HBsAg and HBcrAg levels(log10 U/mL)were measured at baseline and during ninety-six weeks.HBsAg loss rate was evaluated in both groups.Adverse events were recorded in both groups.The kinetic of HBsAg for each treatment group was evaluated from baseline to weeks 24 and 48 by the slope of the HBsAg decline(log10 IU/mL/week)using a linear regression model.RESULTS Sixty-five patients were enrolled,61%receiving tenofovir and 33%entecavir.Thirty-six(55%)were included in Peg-IFN-NA group and 29(44%)in NA group.After matching by age and treatment duration,baseline HBsAg levels were comparable between groups(3.1 vs 3.2)(P=0.25).HBsAg levels at weeks 24,48 and 96 declined in Peg-IFN-NA group(-0.26,-0.40 and-0.44)and remained stable in NA group(-0.10,-0.10 and-0.10)(P<0.05).The slope of HBsAg decline in Peg-IFN-NA group(-0.02)was higher than in NA group(-0.00)(P=0.015).HBcrAg levels did not change.Eight(22%)patients discontinued Peg-IFN due to adverse events.The HBsAg loss was achieved in 3(8.3%)patients of the Peg-IFN-NA group and 0(0%)of the NA group.CONCLUSION The addition of Peg-IFN to NAs caused a greater and faster decrease of HBsAg levels compared to NA therapy.Side effects of Peg-IFN can limit its use in clinical practice. | Teresa Broquetas Montserrat Garcia-Retortillo Miquel Mico Lidia Canillas Marc Puigvehi Nuria Canete Susana Coll Ana Viu Juan Jose Hernandez Xavier Bessa JoseA Carrion | 2020 | World Journal of Hepatology2020，12，11： | 2 |
| 3 | 西班牙抗结核药物所致严重肝毒性反应显示文摘目的:判定抗结核药物引起的严重肝毒性反应的发生频率及发生急性肝功能衰竭或死亡的预报指标。方法﹕西班牙肺科学会成员对1997-2001年18家医院的资料进行回顾性研究。严重肝毒性反应界定为,无临床症状者转氨酶有10倍升高或胆汁郁滞参数3倍增加;有肝炎症状者则为肝功能参数增加或发生肝功能衰竭。采用logistic 回归分析计算比值比(OR)及其95%可信区间(CI)研究其预报因素。结果﹕3510 例中共有166 例发生肝毒性反应,其中90 例(2.56%)为活动性结核病治疗所致。11 例(10.3%)发生急性肝功能衰竭,其中3 例进行了肝移植。总体病死率为4.7%(5 例,其中3 例与饮酒或肝毒性药物有关)。预后不良的预报指标为总胆红素>2mg/dl(OR=9.4 , 95%CI : 1.0-85.5) 及血清肌肝>1.5mg/dl(OR=32.1,95%CI:2.4-424.6)。结论﹕抗结核药物引起的严重肝毒性反应死亡率较高。必须进行经常性的临床检查及临床实验室观察以预防其发生。 | J. R. Tost R. Vidal J. Cayla D. Diaz-Cabanela A. Jimenez J. M. Broquetas 马玙 | 2005 | 结核与肺部疾病杂志2005，8，3： | 2 |
| 4 | Linear and nonlinear terrain deformation maps from a reduced set of interferometric SAR images显示文摘 | Mora O Broquetas A | | 0，，10： | 1 |
| 5 | Linear and nonlin- ear terrain deformation maps from a reduced set of interfero- metric SAR images 显示文摘 | Mora O Mallorqui J J and Broquetas A | 2003 | IEEE Trans Geosci Remote Sens2003，41，： | 1 |
| 6 | The project benefits of Building Information Modelling (BIM)显示文摘 | David Bryde Martí Broquetas Jürgen Marc Volm | 2012 | International Journal of Project Management2012，，： | 1 |
| 7 | Target spinor calibration ( TSC ) for polarimetric radar cross-sectioin measurements显示文摘 | Fabregas X Romeu J Broquetas A | 1995 | Electronics Letters1995，31，19： | 1 |
| 8 | Linear and nonlinear terrain deformation maps from a reduced set of interfero- metric SAR images显示文摘 | Mora O Mallorqui J J Broquetas A | 2003 | IEEE Transactions on Geoscience and Remote Sensing2003，41，10： | 1 |
| 9 | The project benefits of Building Information Modelling(BIM)显示文摘 | David Bryde MartíBroquetas Jürgen Marc Volm | 2013 | International Journal of Project Management2013，31，7： | 1 |
| 10 | Nearly zero inclination geosynchronous SAR mission analysis with long integration time for earth observation 显示文摘 | RUIZ RODON J BROQUETAS A MAKHOUL E | 2014 | IEEE Transactions of Geoscience and Remote Sensing2014，52，10： | 1 |
| 11 | Linear and nonlinear terrain deformation maps from a reduced set of interferometric SAR images显示文摘 | Mora O Mallorqui J J Broquetas A | 2003 | IEEE Transactions on Geoscience and Remote Sensing2003，41，10： | 1 |
| 12 | Linear and nonlinear terrain deformation maps from a reduced set of interferometric SAR images显示文摘 | Mora O Mallorqui J J Broquetas A | 2003 | IEEE Trans Geosci Remote Sens2003，41，10： | 1 |
| 13 | Lung Cancer at a University Hospital: Epidemiological and Histological Characteristics of a Recent and a Historical Series显示文摘 | M.J. Santos-Martínez V. Curull M.L. Blanco F. Macià S. Mojal J. Vila J.M. Broquetas | 2005 | Archivos de Bronconeumología (Internet)2005，，6： | 1 |
| 14 | ARBRES: light-weight CW/FM SAR sensors for small UAVs显示文摘 | Aguasca A Acevo-Herrera R Broquetas A | 2013 | Sen- sors2013，13，3： | 1 |
| 15 | Linear and Nonlinear Terrain Deformation Maps from a Reduced Set of Interferometric SAR Images显示文摘 | MORA O MALLORQUI J BROQUETAS A | 2003 | IEEE Transactions on Geoscience and Remote Sensing2003，41，10： | 1 |
| 16 | A Performance Evaluation of SAR-GMTI Mis- sions for Maritime Applications显示文摘 | MAKHOUL E BROQUETAS A RUIZ RODON J | 2015 | IEEE Trans on Geoscience and Remote Sensing2015，53，5： | 1 |
| 17 | Linear and Nonlinear Terrain Deformation Maps from a Reduced Set of Interferometric SAR Images显示文摘 | MORA O MALLORQUI J J BROQUETAS A | 2003 | IEEE Transactions on Geoscience and Remote Sensing2003，41，： | 1 |
| 18 | Past,present,and future of long-term treatment for hepatitis B virus显示文摘The estimated world prevalence of hepatitis B virus(HBV)infection is 316 million.HBV infection was identified in 1963 and nowadays is a major cause of cirrhosis and hepatocellular carcinoma(HCC)despite universal vaccination programs,and effective antiviral therapy.Long-term administration of nucleos(t)ide analogues(NA)has been the treatment of choice for chronic hepatitis B during the last decades.The NA has shown a good safety profile and high efficacy in controlling viral replication,improving histology,and decreasing the HCC incidence,decompensation,and mortality.However,the low probability of HBV surface antigen seroclearance made necessary an indefinite treatment.The knowledge,in recent years,about the different phases of the viral cycle,and the new insights into the role of the immune system have yielded an increase in new therapeutic approaches.Consequently,several clinical trials evaluating combinations of new drugs with different mechanisms of action are ongoing with promising results.This integrative literature review aims to assess the knowledge and major advances from the past of hepatitis B,the present of NA treatment and withdrawal,and the future perspectives with combined molecules to achieve a functional cure. | Teresa Broquetas José A Carrión | 2023 | World Journal of Gastroenterology2023，29，25： | 1 |
| 19 | Linear and nonlinear terrain de- formation maps from a reduced set of interferometric SAR images 显示文摘 | Mora O Mallorqui J J Broquetas A | 2003 | IEEE Transactions on Geoscience aml Remote Sensing2003，41，10： | 1 |
| 20 | Linear and nonlinear terrain deformation maps from a reduced set of interferometric SAR images显示文摘 | MORA O MALLORQUI J J BROQUETAS A | 2003 | IEEE Transactions on Geoscience and Remote Sensing2003，41，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员